Age \< 18

Hypersensitivity to Imiquimod or to any of the excipients (methylhydroxybenzoate, propylhydroxybenzoate, cetyl alcohol, and stearyl alcohol)

Involvement in a trial of another experimental intervention within 30 days

Life threatening disease

Use of immunosuppressive medications such as oral corticosteroids

Bleeding disorders

Not available for follow-up for 10 weeks

Pregnant, intention to become pregnant during treatment phase of trial, or breastfeeding

Imiquimod for Preventing Keloid Recurrence